Carmeseal-MD (poloxamer 188 NF SC) / Phrixus Pharma, Ethicor - LARVOL DELTA

Safety and Efficacy of P-188 NF in DMD Patients (clinicaltrials.gov) - P2 | N=2 | Terminated | Sponsor: Phrixus Pharmaceuticals, Inc. | N=10 ➔ 2 | Suspended ➔ Terminated; Terminated due to lack of funding.

Enrollment change • Trial termination • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy • TNNI3

Safety and Efficacy of P-188 NF in DMD Patients (clinicaltrials.gov) - P2; N=10; Suspended; Sponsor: Phrixus Pharmaceuticals, Inc.; Trial completion date: Nov 2019 ➔ Nov 2020; Recruiting ➔ Suspended; Trial primary completion date: Sep 2019 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date • Trial suspension